Extensive Stage Small Cell Lung Cancer / Ifinatamab deruxtecan / SCLC · Interventional Study

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

ClinicalTrials.gov · August 7, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registry record for an expanded access program providing ifinatamab deruxtecan to patients with extensively pretreated extensive-stage small cell lung cancer. No outcomes, efficacy data, or safety results are reported in this registration. The record documents access availability only, not clinical evidence.

What was studied

Expanded Access. SCLC, Extensive-stage Small Cell Lung Cancer; age from 18 Years. Intervention: Ifinatamab Deruxtecan. 3 sites: United States.

Key findings

Safety

This is a registry record only; no results, outcomes, efficacy data, or safety information are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a clinical trial registry record for an expanded access program with no results posted; it describes a planned intervention pathway, not clinical evidence of efficacy or safety.

Study design

As stated by the source record.

MethodsExpanded Access

PopulationSCLC, Extensive-stage Small Cell Lung Cancer; age from 18 Years

InterventionIfinatamab Deruxtecan

Setting3 sites: United States

Reported figures

Quoted from the source exactly as published.

Study typeExpanded Access Program

Target populationExtensive-stage SCLC, ≥2 prior lines of treatment

Caveats

This is a registry record only; no results, outcomes, efficacy data, or safety information are reported.
Planned sample size is not specified in this record.
No comparative arm or control group; expanded access programs do not generate controlled trial evidence.
Status is recruitment open; no enrollment or outcome follow-up data are available.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Expanded access program; not a controlled or comparative trial design.

Directness

moderate

Targets extensive-stage SCLC after ≥2 prior lines; directly relevant population.

Consistency

insufficient

Registry record only; no outcomes or comparisons reported.

Risk of bias

insufficient

Expanded access program; no methodology or outcome data to assess bias.

Sample adequacy

insufficient

Planned enrollment not specified; recruitment status is open.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07535359). This is a study registration, not published results. Lead sponsor: Daiichi Sankyo. Recruitment status: AVAILABLE. Study type: EXPANDED_ACCESS. Conditions: SCLC, Extensive-stage Small Cell Lung Cancer. Interventions: DRUG: Ifinatamab Deruxtecan. Brief summary: The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen), and for eligible patients who have no suitable treatment options and are not able to enter a clinical study.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Extensive Stage Small Cell Lung CancerIfinatamab deruxtecanSCLCNCT07535359Daiichi Sankyo